Loading…

Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount

Radiolabelled tumour receptor-binding peptides can be used for in vivo scintigraphic imaging. Recently, the somatostatin analogue [Tyr3]octreotide (D-Phe-c(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr(ol)) was derivatized with the chelator DOTA (tetra-azacyclododecane-tetra-acetic acid), enabling stable radiolabe...

Full description

Saved in:
Bibliographic Details
Published in:European journal of nuclear medicine 1999-07, Vol.26 (7), p.693-698
Main Authors: DE JONG, M, BREEMAN, W. A. P, BERNARD, B. F, VAN GAMEREN, A, DE BRUIN, E, BAKKER, W. H, VAN DER PLUIJM, M. E, VISSER, T. J, MÄCKE, H. R, KRENNING, E. P
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c346t-53a3d2ef82dd28c1d7099b4ffcbd39dccdd7b49d0bc846102850c393f37af4173
cites
container_end_page 698
container_issue 7
container_start_page 693
container_title European journal of nuclear medicine
container_volume 26
creator DE JONG, M
BREEMAN, W. A. P
BERNARD, B. F
VAN GAMEREN, A
DE BRUIN, E
BAKKER, W. H
VAN DER PLUIJM, M. E
VISSER, T. J
MÄCKE, H. R
KRENNING, E. P
description Radiolabelled tumour receptor-binding peptides can be used for in vivo scintigraphic imaging. Recently, the somatostatin analogue [Tyr3]octreotide (D-Phe-c(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr(ol)) was derivatized with the chelator DOTA (tetra-azacyclododecane-tetra-acetic acid), enabling stable radiolabelling with both the high-energy beta particle-emitter yttrium-90 and the Auger electron-emitter indium-111. The thus produced radiolabelled compounds are promising for peptide receptor radionuclide therapy. Our previous in vitro and in vivo (rat) experiments with these radiolabelled compounds showed favourable binding and biodistribution characteristics with high uptake and retention in the target organs. We also demonstrated receptor-specific, time- and temperature-dependent internalization of radiolabelled [DOTA0,Tyr3]octreotide in somatostatin receptor subtype 2 (sst2)-positive rat pancreatic tumour cell lines. In this study we have investigated the effects of differences in the amount of injected peptide on tissue distribution of 111In-labelled [DOTA0, Tyr3]octreotide in normal, i.e. non-tumour-bearing, and CA20948 tumour-bearing rats. This was done in order to find the amount of peptide at which the highest uptake in target tissues is achieved, and thereby to increase the potential of radionuclide therapy while simultaneously ensuring the lowest possible radiotoxicity in normal organs. Uptake of radiolabelled [DOTA0,Tyr3]octreotide in sst2-positive organs showed different bell-shaped functions of the amount of injected peptide, being highest at 0.05 (adrenals), 0.05-0. 1 (pituitary and stomach) and 0.25 (pancreas) microg. Uptake in the tumour was highest at 0.5 microg injected peptide. The highest uptake was found at peptide amounts that were lower than those reported for [111In-DTPA0]octreotide ((D-Phe-c(Cys-Phe-D-Trp-Lys-Thr-Cys)-Thr(ol), DTPA = diethylene-triamine-penta-acetic acid), consistent with the higher receptor affinity of the first compound. Our observations of mass-dependent differences in uptake of radiolabelled [DOTA0, Tyr3]octreotide, being the resultant of a positive effect of increasing amounts of peptide on, for example, receptor clustering and a negative effect of receptor saturation, are of consequence for rat radionuclide therapy studies with radiolabelled peptides and may also be of consequence for human radionuclide therapy studies with this compound.
doi_str_mv 10.1007/s002590050439
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69888969</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69888969</sourcerecordid><originalsourceid>FETCH-LOGICAL-c346t-53a3d2ef82dd28c1d7099b4ffcbd39dccdd7b49d0bc846102850c393f37af4173</originalsourceid><addsrcrecordid>eNpd0cuL1TAUBvAgI947V5duh8DIrKyeNGmbLIfrEwYuyHUhIiVNTsaObVOTdOF_b-4DfKyyyI_vcL5DyHMGrxhA8zoClJUCqEBw9YisWc1U0YBUF2QNXEBRK9WsyGWMDwAgBK-ekBUDrqRk9ZrE_TL6JdBlTvoHUu9o-o40aNv7QXc4DGhp9KNOPiad-onqSQ_-fkH69c1ufwsv6f7LJ_7NmxTQp94i7SO1OONkcUrUT8e8Gefjn86zpvSUPHZ6iPjs_G7I53dv99sPxd3u_cft7V1huKhTUXHNbYlOltaW0jDbgFKdcM50litrjLVNJ5SFzkhRMyhlBYYr7nijnWAN35CbU-4c_M8FY2rHPpq8k57QL7GtcwdS1SrD6__gQ-4kLxrbHFs3UHJxUMVJmeBjDOjaOfSjDr8yag-3aP-5RfZX59SlG9H-pU_lZ_DiDHQ0enBBT6aPf5yUJa-A_wYplpE1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1026702349</pqid></control><display><type>article</type><title>Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount</title><source>Springer Link</source><creator>DE JONG, M ; BREEMAN, W. A. P ; BERNARD, B. F ; VAN GAMEREN, A ; DE BRUIN, E ; BAKKER, W. H ; VAN DER PLUIJM, M. E ; VISSER, T. J ; MÄCKE, H. R ; KRENNING, E. P</creator><creatorcontrib>DE JONG, M ; BREEMAN, W. A. P ; BERNARD, B. F ; VAN GAMEREN, A ; DE BRUIN, E ; BAKKER, W. H ; VAN DER PLUIJM, M. E ; VISSER, T. J ; MÄCKE, H. R ; KRENNING, E. P</creatorcontrib><description>Radiolabelled tumour receptor-binding peptides can be used for in vivo scintigraphic imaging. Recently, the somatostatin analogue [Tyr3]octreotide (D-Phe-c(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr(ol)) was derivatized with the chelator DOTA (tetra-azacyclododecane-tetra-acetic acid), enabling stable radiolabelling with both the high-energy beta particle-emitter yttrium-90 and the Auger electron-emitter indium-111. The thus produced radiolabelled compounds are promising for peptide receptor radionuclide therapy. Our previous in vitro and in vivo (rat) experiments with these radiolabelled compounds showed favourable binding and biodistribution characteristics with high uptake and retention in the target organs. We also demonstrated receptor-specific, time- and temperature-dependent internalization of radiolabelled [DOTA0,Tyr3]octreotide in somatostatin receptor subtype 2 (sst2)-positive rat pancreatic tumour cell lines. In this study we have investigated the effects of differences in the amount of injected peptide on tissue distribution of 111In-labelled [DOTA0, Tyr3]octreotide in normal, i.e. non-tumour-bearing, and CA20948 tumour-bearing rats. This was done in order to find the amount of peptide at which the highest uptake in target tissues is achieved, and thereby to increase the potential of radionuclide therapy while simultaneously ensuring the lowest possible radiotoxicity in normal organs. Uptake of radiolabelled [DOTA0,Tyr3]octreotide in sst2-positive organs showed different bell-shaped functions of the amount of injected peptide, being highest at 0.05 (adrenals), 0.05-0. 1 (pituitary and stomach) and 0.25 (pancreas) microg. Uptake in the tumour was highest at 0.5 microg injected peptide. The highest uptake was found at peptide amounts that were lower than those reported for [111In-DTPA0]octreotide ((D-Phe-c(Cys-Phe-D-Trp-Lys-Thr-Cys)-Thr(ol), DTPA = diethylene-triamine-penta-acetic acid), consistent with the higher receptor affinity of the first compound. Our observations of mass-dependent differences in uptake of radiolabelled [DOTA0, Tyr3]octreotide, being the resultant of a positive effect of increasing amounts of peptide on, for example, receptor clustering and a negative effect of receptor saturation, are of consequence for rat radionuclide therapy studies with radiolabelled peptides and may also be of consequence for human radionuclide therapy studies with this compound.</description><identifier>ISSN: 0340-6997</identifier><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s002590050439</identifier><identifier>PMID: 10398816</identifier><identifier>CODEN: EJNMD9</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Animals ; Biological and medical sciences ; Contrast media. Radiopharmaceuticals ; Indium Radioisotopes ; Medical sciences ; Octreotide - analogs &amp; derivatives ; Octreotide - pharmacokinetics ; Pancreatic Neoplasms - diagnostic imaging ; Pharmacology. Drug treatments ; Radionuclide Imaging ; Radiopharmaceuticals - pharmacokinetics ; Rats ; Rats, Inbred Lew ; Tissue Distribution</subject><ispartof>European journal of nuclear medicine, 1999-07, Vol.26 (7), p.693-698</ispartof><rights>1999 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c346t-53a3d2ef82dd28c1d7099b4ffcbd39dccdd7b49d0bc846102850c393f37af4173</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1882350$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10398816$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DE JONG, M</creatorcontrib><creatorcontrib>BREEMAN, W. A. P</creatorcontrib><creatorcontrib>BERNARD, B. F</creatorcontrib><creatorcontrib>VAN GAMEREN, A</creatorcontrib><creatorcontrib>DE BRUIN, E</creatorcontrib><creatorcontrib>BAKKER, W. H</creatorcontrib><creatorcontrib>VAN DER PLUIJM, M. E</creatorcontrib><creatorcontrib>VISSER, T. J</creatorcontrib><creatorcontrib>MÄCKE, H. R</creatorcontrib><creatorcontrib>KRENNING, E. P</creatorcontrib><title>Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount</title><title>European journal of nuclear medicine</title><addtitle>Eur J Nucl Med</addtitle><description>Radiolabelled tumour receptor-binding peptides can be used for in vivo scintigraphic imaging. Recently, the somatostatin analogue [Tyr3]octreotide (D-Phe-c(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr(ol)) was derivatized with the chelator DOTA (tetra-azacyclododecane-tetra-acetic acid), enabling stable radiolabelling with both the high-energy beta particle-emitter yttrium-90 and the Auger electron-emitter indium-111. The thus produced radiolabelled compounds are promising for peptide receptor radionuclide therapy. Our previous in vitro and in vivo (rat) experiments with these radiolabelled compounds showed favourable binding and biodistribution characteristics with high uptake and retention in the target organs. We also demonstrated receptor-specific, time- and temperature-dependent internalization of radiolabelled [DOTA0,Tyr3]octreotide in somatostatin receptor subtype 2 (sst2)-positive rat pancreatic tumour cell lines. In this study we have investigated the effects of differences in the amount of injected peptide on tissue distribution of 111In-labelled [DOTA0, Tyr3]octreotide in normal, i.e. non-tumour-bearing, and CA20948 tumour-bearing rats. This was done in order to find the amount of peptide at which the highest uptake in target tissues is achieved, and thereby to increase the potential of radionuclide therapy while simultaneously ensuring the lowest possible radiotoxicity in normal organs. Uptake of radiolabelled [DOTA0,Tyr3]octreotide in sst2-positive organs showed different bell-shaped functions of the amount of injected peptide, being highest at 0.05 (adrenals), 0.05-0. 1 (pituitary and stomach) and 0.25 (pancreas) microg. Uptake in the tumour was highest at 0.5 microg injected peptide. The highest uptake was found at peptide amounts that were lower than those reported for [111In-DTPA0]octreotide ((D-Phe-c(Cys-Phe-D-Trp-Lys-Thr-Cys)-Thr(ol), DTPA = diethylene-triamine-penta-acetic acid), consistent with the higher receptor affinity of the first compound. Our observations of mass-dependent differences in uptake of radiolabelled [DOTA0, Tyr3]octreotide, being the resultant of a positive effect of increasing amounts of peptide on, for example, receptor clustering and a negative effect of receptor saturation, are of consequence for rat radionuclide therapy studies with radiolabelled peptides and may also be of consequence for human radionuclide therapy studies with this compound.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Contrast media. Radiopharmaceuticals</subject><subject>Indium Radioisotopes</subject><subject>Medical sciences</subject><subject>Octreotide - analogs &amp; derivatives</subject><subject>Octreotide - pharmacokinetics</subject><subject>Pancreatic Neoplasms - diagnostic imaging</subject><subject>Pharmacology. Drug treatments</subject><subject>Radionuclide Imaging</subject><subject>Radiopharmaceuticals - pharmacokinetics</subject><subject>Rats</subject><subject>Rats, Inbred Lew</subject><subject>Tissue Distribution</subject><issn>0340-6997</issn><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNpd0cuL1TAUBvAgI947V5duh8DIrKyeNGmbLIfrEwYuyHUhIiVNTsaObVOTdOF_b-4DfKyyyI_vcL5DyHMGrxhA8zoClJUCqEBw9YisWc1U0YBUF2QNXEBRK9WsyGWMDwAgBK-ekBUDrqRk9ZrE_TL6JdBlTvoHUu9o-o40aNv7QXc4DGhp9KNOPiad-onqSQ_-fkH69c1ufwsv6f7LJ_7NmxTQp94i7SO1OONkcUrUT8e8Gefjn86zpvSUPHZ6iPjs_G7I53dv99sPxd3u_cft7V1huKhTUXHNbYlOltaW0jDbgFKdcM50litrjLVNJ5SFzkhRMyhlBYYr7nijnWAN35CbU-4c_M8FY2rHPpq8k57QL7GtcwdS1SrD6__gQ-4kLxrbHFs3UHJxUMVJmeBjDOjaOfSjDr8yag-3aP-5RfZX59SlG9H-pU_lZ_DiDHQ0enBBT6aPf5yUJa-A_wYplpE1</recordid><startdate>19990701</startdate><enddate>19990701</enddate><creator>DE JONG, M</creator><creator>BREEMAN, W. A. P</creator><creator>BERNARD, B. F</creator><creator>VAN GAMEREN, A</creator><creator>DE BRUIN, E</creator><creator>BAKKER, W. H</creator><creator>VAN DER PLUIJM, M. E</creator><creator>VISSER, T. J</creator><creator>MÄCKE, H. R</creator><creator>KRENNING, E. P</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>19990701</creationdate><title>Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount</title><author>DE JONG, M ; BREEMAN, W. A. P ; BERNARD, B. F ; VAN GAMEREN, A ; DE BRUIN, E ; BAKKER, W. H ; VAN DER PLUIJM, M. E ; VISSER, T. J ; MÄCKE, H. R ; KRENNING, E. P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c346t-53a3d2ef82dd28c1d7099b4ffcbd39dccdd7b49d0bc846102850c393f37af4173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Contrast media. Radiopharmaceuticals</topic><topic>Indium Radioisotopes</topic><topic>Medical sciences</topic><topic>Octreotide - analogs &amp; derivatives</topic><topic>Octreotide - pharmacokinetics</topic><topic>Pancreatic Neoplasms - diagnostic imaging</topic><topic>Pharmacology. Drug treatments</topic><topic>Radionuclide Imaging</topic><topic>Radiopharmaceuticals - pharmacokinetics</topic><topic>Rats</topic><topic>Rats, Inbred Lew</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DE JONG, M</creatorcontrib><creatorcontrib>BREEMAN, W. A. P</creatorcontrib><creatorcontrib>BERNARD, B. F</creatorcontrib><creatorcontrib>VAN GAMEREN, A</creatorcontrib><creatorcontrib>DE BRUIN, E</creatorcontrib><creatorcontrib>BAKKER, W. H</creatorcontrib><creatorcontrib>VAN DER PLUIJM, M. E</creatorcontrib><creatorcontrib>VISSER, T. J</creatorcontrib><creatorcontrib>MÄCKE, H. R</creatorcontrib><creatorcontrib>KRENNING, E. P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DE JONG, M</au><au>BREEMAN, W. A. P</au><au>BERNARD, B. F</au><au>VAN GAMEREN, A</au><au>DE BRUIN, E</au><au>BAKKER, W. H</au><au>VAN DER PLUIJM, M. E</au><au>VISSER, T. J</au><au>MÄCKE, H. R</au><au>KRENNING, E. P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount</atitle><jtitle>European journal of nuclear medicine</jtitle><addtitle>Eur J Nucl Med</addtitle><date>1999-07-01</date><risdate>1999</risdate><volume>26</volume><issue>7</issue><spage>693</spage><epage>698</epage><pages>693-698</pages><issn>0340-6997</issn><issn>1619-7070</issn><eissn>1619-7089</eissn><coden>EJNMD9</coden><abstract>Radiolabelled tumour receptor-binding peptides can be used for in vivo scintigraphic imaging. Recently, the somatostatin analogue [Tyr3]octreotide (D-Phe-c(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr(ol)) was derivatized with the chelator DOTA (tetra-azacyclododecane-tetra-acetic acid), enabling stable radiolabelling with both the high-energy beta particle-emitter yttrium-90 and the Auger electron-emitter indium-111. The thus produced radiolabelled compounds are promising for peptide receptor radionuclide therapy. Our previous in vitro and in vivo (rat) experiments with these radiolabelled compounds showed favourable binding and biodistribution characteristics with high uptake and retention in the target organs. We also demonstrated receptor-specific, time- and temperature-dependent internalization of radiolabelled [DOTA0,Tyr3]octreotide in somatostatin receptor subtype 2 (sst2)-positive rat pancreatic tumour cell lines. In this study we have investigated the effects of differences in the amount of injected peptide on tissue distribution of 111In-labelled [DOTA0, Tyr3]octreotide in normal, i.e. non-tumour-bearing, and CA20948 tumour-bearing rats. This was done in order to find the amount of peptide at which the highest uptake in target tissues is achieved, and thereby to increase the potential of radionuclide therapy while simultaneously ensuring the lowest possible radiotoxicity in normal organs. Uptake of radiolabelled [DOTA0,Tyr3]octreotide in sst2-positive organs showed different bell-shaped functions of the amount of injected peptide, being highest at 0.05 (adrenals), 0.05-0. 1 (pituitary and stomach) and 0.25 (pancreas) microg. Uptake in the tumour was highest at 0.5 microg injected peptide. The highest uptake was found at peptide amounts that were lower than those reported for [111In-DTPA0]octreotide ((D-Phe-c(Cys-Phe-D-Trp-Lys-Thr-Cys)-Thr(ol), DTPA = diethylene-triamine-penta-acetic acid), consistent with the higher receptor affinity of the first compound. Our observations of mass-dependent differences in uptake of radiolabelled [DOTA0, Tyr3]octreotide, being the resultant of a positive effect of increasing amounts of peptide on, for example, receptor clustering and a negative effect of receptor saturation, are of consequence for rat radionuclide therapy studies with radiolabelled peptides and may also be of consequence for human radionuclide therapy studies with this compound.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>10398816</pmid><doi>10.1007/s002590050439</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0340-6997
ispartof European journal of nuclear medicine, 1999-07, Vol.26 (7), p.693-698
issn 0340-6997
1619-7070
1619-7089
language eng
recordid cdi_proquest_miscellaneous_69888969
source Springer Link
subjects Animals
Biological and medical sciences
Contrast media. Radiopharmaceuticals
Indium Radioisotopes
Medical sciences
Octreotide - analogs & derivatives
Octreotide - pharmacokinetics
Pancreatic Neoplasms - diagnostic imaging
Pharmacology. Drug treatments
Radionuclide Imaging
Radiopharmaceuticals - pharmacokinetics
Rats
Rats, Inbred Lew
Tissue Distribution
title Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T23%3A53%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumour%20uptake%20of%20the%20radiolabelled%20somatostatin%20analogue%20%5BDOTA0,%20TYR3%5Doctreotide%20is%20dependent%20on%20the%20peptide%20amount&rft.jtitle=European%20journal%20of%20nuclear%20medicine&rft.au=DE%20JONG,%20M&rft.date=1999-07-01&rft.volume=26&rft.issue=7&rft.spage=693&rft.epage=698&rft.pages=693-698&rft.issn=0340-6997&rft.eissn=1619-7089&rft.coden=EJNMD9&rft_id=info:doi/10.1007/s002590050439&rft_dat=%3Cproquest_cross%3E69888969%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c346t-53a3d2ef82dd28c1d7099b4ffcbd39dccdd7b49d0bc846102850c393f37af4173%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1026702349&rft_id=info:pmid/10398816&rfr_iscdi=true